How Vor plans to outfox ‘every man and his dog’ in biotech

The early days of cancer cell therapy have long past, and now “every man and his dog are using T cells” to fight tumors, as longtime biotech executive Robert Ang put it.

Which is why Vor Biopharma, which Ang just joined as CEO, is taking a different approach. As STAT’s Kate Sheridan explains, Vor is taking a page from commonplace bone marrow transplants and adding a modern twist. The company’s approach involves editing out a certain protein in hopes of crafting a more effective cell therapy for blood cancer.

Vor’s technology, which Ang called “very elegant and very simple,” is still about 18 months away from a first clinical trial.

Read more.